Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...
Metastasis02:30

Metastasis

Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A reproducible anastomosis in robotic Ivor-Lewis esophagectomy: a simple fix for a persistent problem in a zero-leak consecutive series.

Surgical endoscopy·2026
Same author

Control before crisis: A six-step robotic approach to pulmonary artery management.

JTCVS techniques·2026
Same author

Author Correction: Physiology and immunology of a pig-to-human decedent kidney xenotransplant.

Nature·2026
Same author

Leveraging Commercially Available Protein Assays as Biomarkers for Lung Cancer.

Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology·2026
Same author

Less pain and earlier recovery after extra-thoracic single-port robotic lung resection: a propensity-matched comparison.

Journal of robotic surgery·2026
Same author

The Society of Thoracic Surgeons 2026 Expert Consensus on the Multimodal Treatment of Pleural Mesothelioma.

The Annals of thoracic surgery·2026
Same journal

Nonsteroid treatment options in (pulmonary) sarcoidosis. When to consider and why?

Current opinion in pulmonary medicine·2026
Same journal

Multidisciplinary approach in cardiac sarcoidosis: to biopsy or not?

Current opinion in pulmonary medicine·2026
Same journal

Low diffusion capacity in pulmonary hypertension.

Current opinion in pulmonary medicine·2026
Same journal

Toward precision imaging in interstitial lung disease: advances in quantitative imaging and artificial intelligence.

Current opinion in pulmonary medicine·2026
Same journal

Oxygen therapy in interstitial lung disease - navigating benefit and burden.

Current opinion in pulmonary medicine·2026
Same journal

Preclinical and clinical advances in pulmonary hypertension associated with systemic sclerosis.

Current opinion in pulmonary medicine·2026
See all related articles

Related Experiment Video

Updated: Jul 4, 2026

Implantation and Monitoring by PET/CT of an Orthotopic Model of Human Pleural Mesothelioma in Athymic Mice
07:54

Implantation and Monitoring by PET/CT of an Orthotopic Model of Human Pleural Mesothelioma in Athymic Mice

Published on: December 21, 2019

Malignant mesothelioma 2008.

Michael D Zervos1, Costas Bizekis, Harvey I Pass

  • 1Department of Cardiothoracic Surgery, Division of Thoracic Surgery, New York University School of Medicine, New York, USA. zervom01@med.nyu.edu

Current Opinion in Pulmonary Medicine
|June 4, 2008
PubMed
Summary
This summary is machine-generated.

Malignant mesothelioma is a challenging cancer with poor survival rates. Recent research focuses on novel therapies and tumor markers to improve treatment outcomes for this asbestos-related malignancy.

More Related Videos

Generation and Expansion of Primary, Malignant Pleural Mesothelioma Tumor Lines
08:01

Generation and Expansion of Primary, Malignant Pleural Mesothelioma Tumor Lines

Published on: April 21, 2022

Orthotopic Implantation and Peripheral Immune Cell Monitoring in the II-45 Syngeneic Rat Mesothelioma Model
09:31

Orthotopic Implantation and Peripheral Immune Cell Monitoring in the II-45 Syngeneic Rat Mesothelioma Model

Published on: October 2, 2015

Related Experiment Videos

Last Updated: Jul 4, 2026

Implantation and Monitoring by PET/CT of an Orthotopic Model of Human Pleural Mesothelioma in Athymic Mice
07:54

Implantation and Monitoring by PET/CT of an Orthotopic Model of Human Pleural Mesothelioma in Athymic Mice

Published on: December 21, 2019

Generation and Expansion of Primary, Malignant Pleural Mesothelioma Tumor Lines
08:01

Generation and Expansion of Primary, Malignant Pleural Mesothelioma Tumor Lines

Published on: April 21, 2022

Orthotopic Implantation and Peripheral Immune Cell Monitoring in the II-45 Syngeneic Rat Mesothelioma Model
09:31

Orthotopic Implantation and Peripheral Immune Cell Monitoring in the II-45 Syngeneic Rat Mesothelioma Model

Published on: October 2, 2015

Area of Science:

  • Oncology
  • Thoracic Surgery
  • Medical Research

Background:

  • Malignant mesothelioma is an aggressive pleural cancer with approximately 3000 annual cases in the US.
  • Survival rates for mesothelioma are historically poor, necessitating advancements in treatment.
  • Occupational asbestos exposure is a primary risk factor, with some cases linked to viral exposure (SV40).

Purpose of the Study:

  • To provide a comprehensive overview of malignant mesothelioma.
  • To summarize significant recent and historical research articles on mesothelioma treatment.
  • To review the efficacy of multimodality treatment strategies, including neoadjuvant chemotherapy, extrapleural pneumonectomy, and radiation.

Main Methods:

  • Review of recent clinical trials evaluating combined chemotherapy regimens.
  • Evaluation of novel tumor markers such as osteopontin and mesothelin.
  • Analysis of historical and emerging therapeutic approaches.

Main Results:

  • Emerging research highlights osteopontin and mesothelin as potential new tumor markers for mesothelioma.
  • Phase III trials are investigating the effectiveness of combined chemotherapy regimens.
  • Multimodality treatments, including neoadjuvant chemotherapy, surgery, and radiation, are under continued study.

Conclusions:

  • Malignant mesothelioma remains a difficult-to-treat malignancy.
  • Novel therapies such as intrapleural chemotherapy, photodynamic therapy, and hyperthermic perfusion show promise.
  • Immunomodulating and targeted treatments are currently in Phase I/II trials, indicating ongoing research into advanced therapeutic options.